Review




Structured Review

Servicebio Inc human colorectal cancer cell line ht29
Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated <t>colorectal</t> cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Human Colorectal Cancer Cell Line Ht29, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer cell line ht29/product/Servicebio Inc
Average 90 stars, based on 1 article reviews
human colorectal cancer cell line ht29 - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer"

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

Journal: Cancer Drug Resistance

doi: 10.20517/cdr.2025.35

Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Figure Legend Snippet: Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.

Techniques Used: Quantitative Proteomics, Expressing

Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, * P < 0.05, ** P < 0.01, **** P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.
Figure Legend Snippet: Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, * P < 0.05, ** P < 0.01, **** P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.

Techniques Used: Expressing, Western Blot, Immunohistochemistry, Staining

MAGEA3 inhibits VEGF expression in CRC. (A) The mRNA level of VEGF in the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells; (B and C) Representative images and quantification of Western blot of VEGF in medium of the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells cultured in serum-free medium for 24 h. Ponceau S staining was used as an internal loading control alongside Western blot detection of VEGF; (D) Representative immunohistochemistry (IHC) staining images of MAGEA3 and VEGF in human colorectal cancer (scale bar: 100 μm); (E) Correlation between the IHC scores of MAGEA3 and VEGF in human CRC. * P < 0.05, ** P < 0.01, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; IHC: immunohistochemistry.
Figure Legend Snippet: MAGEA3 inhibits VEGF expression in CRC. (A) The mRNA level of VEGF in the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells; (B and C) Representative images and quantification of Western blot of VEGF in medium of the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells cultured in serum-free medium for 24 h. Ponceau S staining was used as an internal loading control alongside Western blot detection of VEGF; (D) Representative immunohistochemistry (IHC) staining images of MAGEA3 and VEGF in human colorectal cancer (scale bar: 100 μm); (E) Correlation between the IHC scores of MAGEA3 and VEGF in human CRC. * P < 0.05, ** P < 0.01, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; IHC: immunohistochemistry.

Techniques Used: Expressing, Western Blot, Cell Culture, Staining, Control, Immunohistochemistry, shRNA, Negative Control, Over Expression

Rapamycin impacts the inhibitory effect of MAGEA3 on VEGF expression. (A and B) Western blot and quantification of phosphorylated mTOR protein level and total mTOR protein level after knocking down MAGEA3 in HCT116 cells and overexpression of MAGEA3 in HT29 cells; (C) mRNA levels of VEGF in shNC and shMAGEA3 HCT116 cell lines treated or untreated with rapamycin (rapa); (D) mRNA levels of VEGF in EGFP and MAGEA3 overexpression HT29 cell lines treated or untreated with rapamycin. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; rapa: rapamycin.
Figure Legend Snippet: Rapamycin impacts the inhibitory effect of MAGEA3 on VEGF expression. (A and B) Western blot and quantification of phosphorylated mTOR protein level and total mTOR protein level after knocking down MAGEA3 in HCT116 cells and overexpression of MAGEA3 in HT29 cells; (C) mRNA levels of VEGF in shNC and shMAGEA3 HCT116 cell lines treated or untreated with rapamycin (rapa); (D) mRNA levels of VEGF in EGFP and MAGEA3 overexpression HT29 cell lines treated or untreated with rapamycin. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; rapa: rapamycin.

Techniques Used: Expressing, Western Blot, Over Expression, shRNA, Negative Control

MAGEA3 does not activate PDGF, FGF and ANGPT2 in CRC cell lines. (A-C) mRNA levels of PDGF (A), FGF (B), and ANGPT2 (C) in shNC and shMAGEA3 HCT116 cell lines in normoxia and hypoxia & glucose-deprived (Glu(-)) conditions; (D-F) mRNA levels of PDGF (D), FGF (E), and ANGPT2 (F) in HT29 cell lines overexpressing EGFP and MAGEA3 in normoxia and hypoxia & glucose-deprived conditions. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; Glu(-): glucose-deprived; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; ANGPT2: Angiopoietin-2.
Figure Legend Snippet: MAGEA3 does not activate PDGF, FGF and ANGPT2 in CRC cell lines. (A-C) mRNA levels of PDGF (A), FGF (B), and ANGPT2 (C) in shNC and shMAGEA3 HCT116 cell lines in normoxia and hypoxia & glucose-deprived (Glu(-)) conditions; (D-F) mRNA levels of PDGF (D), FGF (E), and ANGPT2 (F) in HT29 cell lines overexpressing EGFP and MAGEA3 in normoxia and hypoxia & glucose-deprived conditions. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; Glu(-): glucose-deprived; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; ANGPT2: Angiopoietin-2.

Techniques Used: shRNA, Negative Control, Over Expression, Derivative Assay

MAGEA3 regulates the mitochondrial capacity of CRC cell lines. (A and B) The extracellular acidification rate (A) and oxygen consumption rate (B) of shNC and shMAGEA3 HCT116 cell lines in Seahorse experiment; (C and D) The extracellular acidification rate (C) and oxygen consumption rate (D) of HT29 cell lines overexpressing EGFP and MAGEA3 in Seahorse experiment. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression.
Figure Legend Snippet: MAGEA3 regulates the mitochondrial capacity of CRC cell lines. (A and B) The extracellular acidification rate (A) and oxygen consumption rate (B) of shNC and shMAGEA3 HCT116 cell lines in Seahorse experiment; (C and D) The extracellular acidification rate (C) and oxygen consumption rate (D) of HT29 cell lines overexpressing EGFP and MAGEA3 in Seahorse experiment. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression.

Techniques Used: shRNA, Negative Control, Over Expression



Similar Products

96
ATCC human colorectal cancer cell lines ht29
A. Percentage of Cleaved Caspase 3/7 positive <t>HT29</t> (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.
Human Colorectal Cancer Cell Lines Ht29, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer cell lines ht29/product/ATCC
Average 96 stars, based on 1 article reviews
human colorectal cancer cell lines ht29 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

99
ATCC human colorectal cancer cell line ht29
A. Percentage of Cleaved Caspase 3/7 positive <t>HT29</t> (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.
Human Colorectal Cancer Cell Line Ht29, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer cell line ht29/product/ATCC
Average 99 stars, based on 1 article reviews
human colorectal cancer cell line ht29 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
ATCC ht29 human colorectal cancer cell lines
The clinical significance of TIMP1 in CRC and in vitro study. A , B . Evaluation of silencing efficiency of siRNA in CRC cell lines; C . MTT and Cell colony forming assays are used to assess the influence of blocking TIMP1 expressions on proliferative abilities of HCT116 and <t>HT29</t> cells; D . The transwell assays revealed that silencing of TIMP1 inhibited the migration and invasion of CRC cells; E . The apoptosis observed after knocking down TIMP1 in CRC cells. All experiments and analyses were performed in triplicate to ensure accuracy and reliability. Numerical data are displayed as the mean ± standard deviation (SD). siRNA Small interfering RNA; Control: Blank control group; NC : Negative control group; ** means p value < 0.01; *** means p value < 0.001
Ht29 Human Colorectal Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ht29 human colorectal cancer cell lines/product/ATCC
Average 99 stars, based on 1 article reviews
ht29 human colorectal cancer cell lines - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Servicebio Inc human colorectal cancer cell line ht29
Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated <t>colorectal</t> cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Human Colorectal Cancer Cell Line Ht29, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer cell line ht29/product/Servicebio Inc
Average 90 stars, based on 1 article reviews
human colorectal cancer cell line ht29 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

99
ATCC human colorectal cancer crc cell lines ht29
Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated <t>colorectal</t> cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Human Colorectal Cancer Crc Cell Lines Ht29, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal cancer crc cell lines ht29/product/ATCC
Average 99 stars, based on 1 article reviews
human colorectal cancer crc cell lines ht29 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Thermo Fisher ht29 human colorectal cancer cell line
Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated <t>colorectal</t> cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.
Ht29 Human Colorectal Cancer Cell Line, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ht29 human colorectal cancer cell line/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
ht29 human colorectal cancer cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A. Percentage of Cleaved Caspase 3/7 positive HT29 (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.

Journal: bioRxiv

Article Title: Molidustat Targets a Synthetic Lethal Vulnerability in APC-Mutant Colorectal Cancer through GSTP1 and PHD2 Co-Inhibition

doi: 10.64898/2026.01.31.702998

Figure Lengend Snippet: A. Percentage of Cleaved Caspase 3/7 positive HT29 (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.

Article Snippet: Human colorectal cancer cell lines HT29 and RKO were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, D6429) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco, 16000044), 1% (v/v) penicillin-streptomycin (Gibco, 15140122), and 2 mM L-glutamine (Sigma-Aldrich, G7513).

Techniques: Positive Control, Two Tailed Test, Western Blot, Transfection

The clinical significance of TIMP1 in CRC and in vitro study. A , B . Evaluation of silencing efficiency of siRNA in CRC cell lines; C . MTT and Cell colony forming assays are used to assess the influence of blocking TIMP1 expressions on proliferative abilities of HCT116 and HT29 cells; D . The transwell assays revealed that silencing of TIMP1 inhibited the migration and invasion of CRC cells; E . The apoptosis observed after knocking down TIMP1 in CRC cells. All experiments and analyses were performed in triplicate to ensure accuracy and reliability. Numerical data are displayed as the mean ± standard deviation (SD). siRNA Small interfering RNA; Control: Blank control group; NC : Negative control group; ** means p value < 0.01; *** means p value < 0.001

Journal: Discover Oncology

Article Title: Bioinformatics mining and experimental validation of prognostic biomarkers in colorectal cancer

doi: 10.1007/s12672-025-03301-9

Figure Lengend Snippet: The clinical significance of TIMP1 in CRC and in vitro study. A , B . Evaluation of silencing efficiency of siRNA in CRC cell lines; C . MTT and Cell colony forming assays are used to assess the influence of blocking TIMP1 expressions on proliferative abilities of HCT116 and HT29 cells; D . The transwell assays revealed that silencing of TIMP1 inhibited the migration and invasion of CRC cells; E . The apoptosis observed after knocking down TIMP1 in CRC cells. All experiments and analyses were performed in triplicate to ensure accuracy and reliability. Numerical data are displayed as the mean ± standard deviation (SD). siRNA Small interfering RNA; Control: Blank control group; NC : Negative control group; ** means p value < 0.01; *** means p value < 0.001

Article Snippet: HCT116 and HT29 human colorectal cancer cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Thermo Fisher Scientific, USA) with 10% fetal bovine serum, and 1% penicillin and streptomycin.

Techniques: In Vitro, Blocking Assay, Migration, Standard Deviation, Small Interfering RNA, Control, Negative Control

Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331 . The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P -value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log( P -value) from two survival analyses. The X-axis represents the -log( P -value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log( P -value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log( P -value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: Quantitative Proteomics, Expressing

Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, * P < 0.05, ** P < 0.01, **** P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, * P < 0.05, ** P < 0.01, **** P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: Expressing, Western Blot, Immunohistochemistry, Staining

MAGEA3 inhibits VEGF expression in CRC. (A) The mRNA level of VEGF in the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells; (B and C) Representative images and quantification of Western blot of VEGF in medium of the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells cultured in serum-free medium for 24 h. Ponceau S staining was used as an internal loading control alongside Western blot detection of VEGF; (D) Representative immunohistochemistry (IHC) staining images of MAGEA3 and VEGF in human colorectal cancer (scale bar: 100 μm); (E) Correlation between the IHC scores of MAGEA3 and VEGF in human CRC. * P < 0.05, ** P < 0.01, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; IHC: immunohistochemistry.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: MAGEA3 inhibits VEGF expression in CRC. (A) The mRNA level of VEGF in the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells; (B and C) Representative images and quantification of Western blot of VEGF in medium of the shNC and shMAGEA3 groups of HCT116 cells, and the EGFP and MAGEA3-OE groups of HT29 cells cultured in serum-free medium for 24 h. Ponceau S staining was used as an internal loading control alongside Western blot detection of VEGF; (D) Representative immunohistochemistry (IHC) staining images of MAGEA3 and VEGF in human colorectal cancer (scale bar: 100 μm); (E) Correlation between the IHC scores of MAGEA3 and VEGF in human CRC. * P < 0.05, ** P < 0.01, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; IHC: immunohistochemistry.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: Expressing, Western Blot, Cell Culture, Staining, Control, Immunohistochemistry, shRNA, Negative Control, Over Expression

Rapamycin impacts the inhibitory effect of MAGEA3 on VEGF expression. (A and B) Western blot and quantification of phosphorylated mTOR protein level and total mTOR protein level after knocking down MAGEA3 in HCT116 cells and overexpression of MAGEA3 in HT29 cells; (C) mRNA levels of VEGF in shNC and shMAGEA3 HCT116 cell lines treated or untreated with rapamycin (rapa); (D) mRNA levels of VEGF in EGFP and MAGEA3 overexpression HT29 cell lines treated or untreated with rapamycin. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; rapa: rapamycin.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: Rapamycin impacts the inhibitory effect of MAGEA3 on VEGF expression. (A and B) Western blot and quantification of phosphorylated mTOR protein level and total mTOR protein level after knocking down MAGEA3 in HCT116 cells and overexpression of MAGEA3 in HT29 cells; (C) mRNA levels of VEGF in shNC and shMAGEA3 HCT116 cell lines treated or untreated with rapamycin (rapa); (D) mRNA levels of VEGF in EGFP and MAGEA3 overexpression HT29 cell lines treated or untreated with rapamycin. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; rapa: rapamycin.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: Expressing, Western Blot, Over Expression, shRNA, Negative Control

MAGEA3 does not activate PDGF, FGF and ANGPT2 in CRC cell lines. (A-C) mRNA levels of PDGF (A), FGF (B), and ANGPT2 (C) in shNC and shMAGEA3 HCT116 cell lines in normoxia and hypoxia & glucose-deprived (Glu(-)) conditions; (D-F) mRNA levels of PDGF (D), FGF (E), and ANGPT2 (F) in HT29 cell lines overexpressing EGFP and MAGEA3 in normoxia and hypoxia & glucose-deprived conditions. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; Glu(-): glucose-deprived; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; ANGPT2: Angiopoietin-2.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: MAGEA3 does not activate PDGF, FGF and ANGPT2 in CRC cell lines. (A-C) mRNA levels of PDGF (A), FGF (B), and ANGPT2 (C) in shNC and shMAGEA3 HCT116 cell lines in normoxia and hypoxia & glucose-deprived (Glu(-)) conditions; (D-F) mRNA levels of PDGF (D), FGF (E), and ANGPT2 (F) in HT29 cell lines overexpressing EGFP and MAGEA3 in normoxia and hypoxia & glucose-deprived conditions. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression; Glu(-): glucose-deprived; PDGF: Platelet-derived growth factor; FGF: Fibroblast growth factor; ANGPT2: Angiopoietin-2.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: shRNA, Negative Control, Over Expression, Derivative Assay

MAGEA3 regulates the mitochondrial capacity of CRC cell lines. (A and B) The extracellular acidification rate (A) and oxygen consumption rate (B) of shNC and shMAGEA3 HCT116 cell lines in Seahorse experiment; (C and D) The extracellular acidification rate (C) and oxygen consumption rate (D) of HT29 cell lines overexpressing EGFP and MAGEA3 in Seahorse experiment. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression.

Journal: Cancer Drug Resistance

Article Title: Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

doi: 10.20517/cdr.2025.35

Figure Lengend Snippet: MAGEA3 regulates the mitochondrial capacity of CRC cell lines. (A and B) The extracellular acidification rate (A) and oxygen consumption rate (B) of shNC and shMAGEA3 HCT116 cell lines in Seahorse experiment; (C and D) The extracellular acidification rate (C) and oxygen consumption rate (D) of HT29 cell lines overexpressing EGFP and MAGEA3 in Seahorse experiment. ns: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. shNC: shRNA for negative control; MAGEA3-OE: MAGEA3 overexpression.

Article Snippet: The human colorectal cancer cell line HCT116 was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and the human colorectal cancer cell line HT29 was obtained from Servicebio Technology, China (STCC10801P).

Techniques: shRNA, Negative Control, Over Expression